Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | HTR1D | P28221 | 1/20 | 0.37 |
| ▸ | HTR1B | P28222 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR1E | P28566 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27593168 | 0.85 | SLC6A2 (0.40) | ALDH1A1KDM4EHSD17B10SLC6A2SLC6A4 | |
| SCHEMBL932659 | 0.79 | TAAR1 (0.48) | SLC6A2SLC6A4SLC6A3TAAR1MAOA | |
| SCHEMBL14478276 | 0.79 | — | — | |
| SCHEMBL13692285 | 0.79 | — | — | |
| SCHEMBL2022682 | 0.79 | — | — | |
| SCHEMBL2857779 | 0.76 | SLC6A2 (0.61) | SLC6A2SLC6A4SLC6A3TAAR1MAOA | |
| SCHEMBL3506512 | 0.75 | ALDH1A1 (0.54) | ALDH1A1KDM4EHSD17B10SLC6A2SLC6A4 | |
| SCHEMBL5461044 | 0.75 | SLC6A2 (0.37) | ALDH1A1KDM4EHSD17B10SLC6A2SLC6A4 | |
| SCHEMBL711505 | 0.73 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3TAAR1MAOA | |
| SCHEMBL8146532 | 0.72 | ALDH1A1 (0.54) | ALDH1A1KDM4EHSD17B10HTR2BKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1370 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9770514-B2 | Tamper-resistant pharmaceutical dosage forms | ExxPharma Therapeutics LLC (US) | 2017-09-26 | — | — | US | claimed |
| US-20160067271-A1 | Methods And Compositions For Preventing Or Treating Obesity | NORTHEASTERN UNIVERSITY | 2016-03-10 | — | — | US | claimed |
| US-20150272920-A1 | METHOD FOR TREATING OBESITY WITH ANTI-OBESITY FORMULATIONS AND OMEGA 3 FATTY ACIDS FOR THE REDUCTION OF BODY WEIGHT IN CARDIOVASCULAR DISEASE PATIENTS (CVD) AND DIABETICS | PIVOTAL THERAPEUTICS INC. (CA) | 2015-10-01 | — | — | US | claimed |
| US-20150064250-A1 | Tamper-Resistant Pharmaceutical Dosage Forms | ExxPharma Therapeutics LLC (US) | 2015-03-05 | — | — | US | claimed |
| EP-2814478-A1 | A METHOD FOR TREATING OBESITY WITH ANTI-OBESITY FORMULATIONS AND OMEGA 3 FATTY ACIDS FOR THE REDUCTION OF BODY WEIGHT IN CARDIOVASCULAR DISEASE PATIENTS (CVD) AND DIABETICS | Pivotal Therapeutics, Inc. (CA) | 2014-12-24 | — | — | EP | claimed |
| US-8715648-B2 | Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics | PIVOTAL THERAPEUTICS INC. (CA) | 2014-05-06 | — | — | US | claimed |
| EP-2675444-A1 | A FORMULATIONS COMPRISING OMEGA 3 FATTY ACIDS AND AN ANTI OBESITY AGENT FOR THE REDUCTION OF BODY WEIGHT IN CARDIOVASCULAR DISEASE PATIENTS (CVD) AND DIABETICS | Pivotal Therapeutics, Inc. (CA) | 2013-12-25 | — | — | EP | claimed |
| US-20130324461-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING OBESITY | SITKOVSKY MICHAIL V (US) | 2013-12-05 | — | — | US | claimed |
| WO-2013122622-A1 | A METHOD FOR TREATING OBESITY WITH ANTI-OBESITY FORMULATIONS AND OMEGA 3 FATTY ACIDS FOR THE REDUCTION OF BODY WEIGHT IN CARDIOVASCULAR DISEASE PATIENTS (CVD) AND DIABETICS | PIVOTAL THERAPEUTICS, INC. (CA) | 2013-08-22 | — | — | WO | claimed |
| EP-2608794-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING OBESITY | Northeastern University (US) | 2013-07-03 | — | — | EP | claimed |
| WO-2003063781-A2 | SUBSTITUTED IMIDAZOLES AS CANNABINOID RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2003-08-07 | — | — | WO | claimed |
| US-20030114495-A1 | Substituted imidazoles as cannabinoid receptor modulators | MERCK SHARP & DOHME CORP. | 2003-06-19 | — | — | US | claimed |
| WO-2003045313-A2 | 2-AMINOQUINOLINE COMPOUNDS | MERCK & CO. INC. (US) | 2003-06-05 | — | — | WO | claimed |
| WO-2003045920-A1 | 4-AMINOQUINOLINE COMPOUNDS | MERCK & CO., INC. (US) | 2003-06-05 | — | — | WO | claimed |
| WO-2003007887-A2 | SUBSTITUTED IMIDAZOLES AS CANNABINOID RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2003-01-30 | — | — | WO | claimed |
| JP-2001524960-A | — | — | 2001-12-04 | — | — | JP | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| EP-0977572-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING EATING DISORDERS | MERCK SHARP & DOHME LTD. (GB) | 2000-02-09 | — | — | EP | claimed |
| WO-1998047513-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING EATING DISORDERS | MERCK SHARP & DOHME LIMITED (GB) | 1998-10-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130324461-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING OBESITY | ADORA2A, ADORA3, ADORA1 | ALDH1A1 1084/4885KDM4E 2379/4885HSD17B10 1849/4885 |
| US-20160067271-A1 | Methods And Compositions For Preventing Or Treating Obesity | ADORA2A, ADORA3, ADORA1 | ALDH1A1 1084/4885KDM4E 2379/4885HSD17B10 1849/4885 |
| US-20030114495-A1 | Substituted imidazoles as cannabinoid receptor modulators | CNR1, CNR2, GPR119 | ALDH1A1 3232/4885KDM4E 1781/4885HSD17B10 4747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.